Kadimastem and iTolerance Successfully Meet with FDA
Advancing a promising future for diabetes treatment, Kadimastem and iTolerance have successfully completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). Their collaborative effort focuses on iTOL-102, an innovative treatment for Type 1 Diabetes, which holds the potential to cure this chronic condition without the requirement of lifelong immune suppression.
Innovative Approach to Diabetes Treatment
The joint initiative between Kadimastem and iTolerance aims to develop iTOL-102, utilizing Kadimastem's proprietary IsletRx cells derived from human stem cells combined with iTolerance's immunomodulatory innovations. This combination is designed to foster insulin production while minimizing the need for continuous immunosuppression, which is often required after transplants.
Significance of Pre-IND Meeting
The completion of the pre-IND meeting represents a pivotal moment in their journey toward clinical trials. Both companies consider the feedback from the FDA invaluable as it provides direction for their upcoming safety studies and plans for a First-in-Human clinical trial. This feedback is crucial for refining their development strategy and ensuring compliance with regulatory standards.
Research and Development Journey
iTOL-102 is under evaluation at the Diabetes Research Institute, known for its commitment to groundbreaking methods in diabetes treatment. Preliminary studies have indicated that iTOL-102 may induce functional insulin release and reverse the disease in animal models, a promising indicator for human applications.
Collaboration Brings Hope to Patients
The partnership between Kadimastem and iTolerance is not just about scientific innovation but also about bringing hope to millions affected by Type 1 Diabetes. Dr. Anthony Japour, CEO of iTolerance, expressed optimism about the FDA's positive reception of their approach, stating it is a crucial milestone that validates their efforts to develop a potentially game-changing therapy.
Future Directions for iTOL-102
Both companies are diligently working towards enhancing the efficacy of iTOL-100, designed to work with Kadimastem's IsletRx cells. These developments suggest a strong alliance focused on navigating the complexities of regulatory pathways while prioritizing patient safety and treatment effectiveness. Kadimastem's innovative product IsletRx aims to address the persistent shortage of donor islets by providing a scalable source of insulin-producing cells, highlighting their commitment to advancing diabetes treatments.
Leadership Commitment
Executives from both companies, including Ronen Twito, Kadimastem's CEO, emphasize the important results emerging from their research, showcasing a shared vision for transforming diabetes treatment. Their collaboration with the FDA serves as a solid foundation for future endeavors, aiming to make a meaningful impact on patients' lives.
About Kadimastem
Kadimastem, traded on the Tel Aviv Stock Exchange (KDST), specializes in innovative cell therapy products aimed at Neurodegenerative Diseases and diabetes. IsletRx, their flagship diabetes treatment, consists of advanced pancreatic islet cells that not only regulate insulin but potentially pave the way for a cure. The company was founded by Professor Michel Revel, who also pioneered significant treatments for other diseases.
About iTolerance
iTolerance, a regenerative medicine entity, is focused on creating technologies that allow for effective tissue and organ transplantations without the lifelong requirement of immunosuppression. Their lead product, iTOL-100, utilizes cutting-edge technology aimed at promoting local immune tolerance, presenting an impactful solution for Type 1 Diabetes.
Frequently Asked Questions
What is the significance of the pre-IND meeting with the FDA?
The pre-IND meeting is crucial as it provides vital feedback from the FDA, guiding the next steps for clinical development and safety studies of iTOL-102.
How does iTOL-102 work?
iTOL-102 combines Kadimastem's human stem cell-derived pancreatic islets with iTolerance's immunomodulatory technologies to promote functional insulin release without requiring lifelong immunosuppression.
What are IsletRx cells?
IsletRx cells are clinical-grade pancreatic islet-like cells derived from human stem cells that can produce insulin, addressing the global donor islet shortage.
What future developments can we expect for iTOL-102?
Following FDA feedback, Kadimastem and iTolerance are refining their clinical trial plans, moving toward implementing their safety toxicology studies.
Who are the key leaders in this collaboration?
Key leaders include Dr. Anthony Japour of iTolerance and Ronen Twito of Kadimastem, both of whom are committed to advancing the treatment of Type 1 Diabetes through their partnership.
